Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

243 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome.
Avallone A, Aloj L, Caracò C, Delrio P, Pecori B, Tatangelo F, Scott N, Casaretti R, Di Gennaro F, Montano M, Silvestro L, Budillon A, Lastoria S. Avallone A, et al. Among authors: silvestro l. Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1848-57. doi: 10.1007/s00259-012-2229-2. Epub 2012 Oct 5. Eur J Nucl Med Mol Imaging. 2012. PMID: 23053320 Clinical Trial.
A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients.
D'Alterio C, Avallone A, Tatangelo F, Delrio P, Pecori B, Cella L, Pelella A, D'Armiento FP, Carlomagno C, Bianco F, Silvestro L, Pacelli R, Napolitano M, Iaffaioli RV, Scala S. D'Alterio C, et al. Among authors: silvestro l. Int J Cancer. 2014 Jul 15;135(2):379-90. doi: 10.1002/ijc.28689. Epub 2014 Jan 10. Int J Cancer. 2014. PMID: 24375277 Free article.
Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial).
Avallone A, Piccirillo MC, Delrio P, Pecori B, Di Gennaro E, Aloj L, Tatangelo F, D'Angelo V, Granata C, Cavalcanti E, Maurea N, Maiolino P, Bianco F, Montano M, Silvestro L, Terranova Barberio M, Roca MS, Di Maio M, Marone P, Botti G, Petrillo A, Daniele G, Lastoria S, Iaffaioli VR, Romano G, Caracò C, Muto P, Gallo C, Perrone F, Budillon A. Avallone A, et al. Among authors: silvestro l. BMC Cancer. 2014 Nov 24;14:875. doi: 10.1186/1471-2407-14-875. BMC Cancer. 2014. PMID: 25421252 Free PMC article. Clinical Trial.
Italian Oncological Pain Survey (IOPS): a multicentre Italian study of breakthrough pain performed in different settings.
Mercadante S, Lazzari M, Reale C, Cuomo A, Fusco F, Marchetti P, Mediati RD, Chiurazzi B, Ciuffedra L, Caraceni A, Iaffaioli V, Luzzani M, Micheletto G, Papa A, Raffaeli W, Valle A, Caruso M, Di Costanzo F, Pinato G, Nardi F, Barni S, Natoli S, Mammucari M, Sabato AF, Dauri M; IOPS Study Group. Mercadante S, et al. Clin J Pain. 2015 Mar;31(3):214-21. doi: 10.1097/AJP.0000000000000161. Clin J Pain. 2015. PMID: 25654429
Diabetes and Body Mass Index Are Associated with Neuropathy and Prognosis in Colon Cancer Patients Treated with Capecitabine and Oxaliplatin Adjuvant Chemotherapy.
Ottaiano A, Nappi A, Tafuto S, Nasti G, De Divitiis C, Romano C, Cassata A, Casaretti R, Silvestro L, Avallone A, Capuozzo M, Capozzi M, Maiolino P, Quagliariello V, Scala S, Iaffaioli VR. Ottaiano A, et al. Among authors: silvestro l. Oncology. 2016;90(1):36-42. doi: 10.1159/000442527. Epub 2016 Jan 6. Oncology. 2016. PMID: 26731722
Breakthrough Cancer Pain: Preliminary Data of The Italian Oncologic Pain Multisetting Multicentric Survey (IOPS-MS).
Mercadante S, Marchetti P, Cuomo A, Caraceni A, Mediati RD, Mammucari M, Natoli S, Lazzari M, Dauri M, Airoldi M, Azzarello G, Bandera M, Blasi L, Cartenì G, Chiurazzi B, Costanzo BVP, Degiovanni D, Fusco F, Guardamagna V, Iaffaioli V, Liguori S, Lorusso V, Mameli S, Mattioli R, Mazzei T, Melotti RM, Menardo V, Miotti D, Moroso S, De Santis S, Orsetti R, Papa A, Ricci S, Sabato AF, Scelzi E, Sofia M, Tonini G, Aielli F, Valle A; IOPS MS study group. Mercadante S, et al. Adv Ther. 2017 Jan;34(1):120-135. doi: 10.1007/s12325-016-0440-4. Epub 2016 Nov 21. Adv Ther. 2017. PMID: 27873235 Free PMC article.
First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis.
Ottaiano A, De Stefano A, Capozzi M, Nappi A, De Divitiis C, Romano C, Silvestro L, Cassata A, Casaretti R, Tafuto S, Caraglia M, Berretta M, Nasti G, Avallone A. Ottaiano A, et al. Among authors: silvestro l. Front Pharmacol. 2018 May 3;9:441. doi: 10.3389/fphar.2018.00441. eCollection 2018. Front Pharmacol. 2018. PMID: 29773991 Free PMC article. Review.
243 results